Current and Emerging Treatments in Small Cell Lung Cancer
Kristin Higgins, MD, Winship Cancer Institute, Atlanta, Georgia, provides an overview of the current and future treatment options for patients with small cell lung cancer, a topic she presented at the 2022 Great Debates & Updates in Lung Cancers meeting in New York.
In her presentation, Dr Higgins discussed chemo-immunotherapy, radiation added to chemo-immunotherapy, and ongoing trials focused on the treatment of small cell lung cancer.
Transcript
Hello, I'm Dr. Kristin Higgins, a thoracic radiation oncologist and associate professor at Winship Cancer Institute of Emory University. I'm here at the Great Debates and Updates in Lung Cancer Conference in Brooklyn, New York.
One of the important areas of therapeutic improvement in lung cancer is in the treatment of small cell lung cancer. We've seen immunotherapy become standard of care, now in combination with chemotherapy for extensive stage small cell lung cancer.
We're also looking at how radiation added to that chemoimmunotherapy backbone could further improve upon outcomes in extensive stage small cell lung cancer. I'm most excited about looking at moving immunotherapy into curable forms of small cell lung cancer.
We have 2 recent trials that have completed accrual, the ADRIATIC study, and NRG-LU005. These trials both evaluate the use of immunotherapy with chemoradiation, and we expect to see the results of these trials sometime within the next few years. We hope that this will further improve survival rates for patients with curable forms of small cell lung cancer.
Source
Higgins K. Current Controversies in SCLC: PCI, Thoracic XRT in Ext SCLC; BID vs QD RT in Limited SCLC. Presented at: Great Debates & Updates in Lung Cancer; October 14-15, 2022; Brooklyn, New York.
